Cancer Research Meeting Calendar Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasumi, Y.
Right arrow Articles by Ozawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasumi, Y.
Right arrow Articles by Ozawa, K.
[Cancer Research 62, 2019-2023, April 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Soluble FLT-1 Expression Suppresses Carcinomatous Ascites in Nude Mice Bearing Ovarian Cancer1

Yoko Hasumi, Hiroaki Mizukami, Masashi Urabe, Takahiro Kohno, Koichi Takeuchi, Akihiro Kume, Mikio Momoeda, Hiroyuki Yoshikawa, Takashi Tsuruo, Masabumi Shibuya, Yuji Taketani and Keiya Ozawa2

Division of Genetic Therapeutics [Y. H., H. M., M. U., T. K., A. K., K. O.] and Department of Anatomy, Jichi Medical School [K. T.], Tochigi 329-0498, and Department of Obstetrics and Gynecology, Faculty of Medicine 113-0033 [Y. H., M. M., H. Y., Y. T.], Institute of Molecular and Cellular Biosciences 113-0032 [T. T.], and Department of Genetics, Institute of Medical Science, University of Tokyo, Tokyo 108-8639 [M. S.], Japan

Vascular endothelial growth factor (VEGF), a bifunctional protein enhancing vascular permeability and stimulating endothelial growth, is thought to be responsible for fluid accumulation and angiogenesis in ascites tumors. To investigate the effects of stable expression of the soluble form of Flt-1 VEGF receptor (sFlt-1), a known endogenous inhibitor of VEGF, on the malignant ascites tumors, we cotransduced RMG-1 human ovarian cancer cells with adeno-associated virus vectors carrying the sFlt-1 cDNA and Neo gene or Neo gene alone and isolated both the sFlt-1-expressing clone and the Neo-expressing clone. In vitro growth characteristics were essentially the same. As expected, conditioned medium collected from the sFlt-1-expressing cells significantly inhibited the human umbilical vein endothelial cell proliferation in the presence of recombinant VEGF. Expression of sFlt-1 significantly suppressed RMG-1 cell-induced angiogenesis in vivo in the mouse dorsal air sac assay model. We then inoculated sFlt-1- or Neo alone-expressing cells i.p. into female BALB/c nude mice. The average volume of ascites fluid, number of leaked RBCs, and number of cancer cells were significantly lower in mice injected with sFlt-1-expressing cells than in the controls. Survival time was significantly prolonged in mice injected with sFlt-1-expressing cells. These results suggest that inhibition of VEGF activity by sFlt-1 expression may provide a means to control carcinomatous ascites and angiogenesis of malignant ascites tumors.




This article has been cited by other articles:


Home page
 IOVSHome page
C.-M. Lai, M. J. Estcourt, M. Wikstrom, R. P. Himbeck, N. L. Barnett, M. Brankov, L. B. G. Tee, S. A. Dunlop, M. A. Degli-Esposti, and E. P. Rakoczy
rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector
Invest. Ophthalmol. Vis. Sci., September 1, 2009; 50(9): 4279 - 4287.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. M. Ptaszynska, M. L. Pendrak, R. W. Bandle, M. L. Stracke, and D. D. Roberts
Positive Feedback between Vascular Endothelial Growth Factor-A and Autotaxin in Ovarian Cancer Cells
Mol. Cancer Res., March 1, 2008; 6(3): 352 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Huynh, C. C. M. Teo, and K. C. Soo
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer
Mol. Cancer Ther., November 1, 2007; 6(11): 2959 - 2966.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, D. Sheikh-Hamad, S. Liu, S. D. Cho, K. Yoon, and S. Safe
Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4 in Pancreatic Cancer Cells
Cancer Res., April 1, 2007; 67(7): 3286 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris
Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice.
Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Schmidt, J. Hoffend, A. Altmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, B. Engelhardt, D. Koczan, J. Peter, S. Vorwald, H. Eskerski, et al.
Transfer of the sFLT-1 Gene in Morris Hepatoma Results in Decreased Growth and Perfusion and Induction of Genes Associated with Stress Response
Clin. Cancer Res., March 15, 2005; 11(6): 2132 - 2140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Isayeva, C. Ren, and S. Ponnazhagan
Recombinant Adeno-Associated Virus 2-Mediated Antiangiogenic Prevention in a Mouse Model of Intraperitoneal Ovarian Cancer
Clin. Cancer Res., February 1, 2005; 11(3): 1342 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Elkin, A. Orgel, and H. K. Kleinman
An Angiogenic Switch in Breast Cancer Involves Estrogen and Soluble Vascular Endothelial Growth Factor Receptor 1
J Natl Cancer Inst, June 2, 2004; 96(11): 875 - 878.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. T. Byrne, L. Ross, J. Holash, M. Nakanishi, L. Hu, J. I. Hofmann, G. D. Yancopoulos, and R. B. Jaffe
Vascular Endothelial Growth Factor-Trap Decreases Tumor Burden, Inhibits Ascites, and Causes Dramatic Vascular Remodeling in an Ovarian Cancer Model
Clin. Cancer Res., November 15, 2003; 9(15): 5721 - 5728.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cuadros, A. L. Dominguez, G. I. Frost, P. Borgstrom, and J. Lustgarten
Cooperative Effect between Immunotherapy and Antiangiogenic Therapy Leads to Effective Tumor Rejection in Tolerant Her-2/neu Mice
Cancer Res., September 15, 2003; 63(18): 5895 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Mahasreshti, M. Kataram, M. H. Wang, C. R. Stockard, W. E. Grizzle, D. Carey, G. P. Siegal, H. J. Haisma, R. D. Alvarez, and D. T. Curiel
Intravenous Delivery of Adenovirus-mediated Soluble FLT-1 Results in Liver Toxicity
Clin. Cancer Res., July 1, 2003; 9(7): 2701 - 2710.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Sugimoto, Y. Hamano, D. Charytan, D. Cosgrove, M. Kieran, A. Sudhakar, and R. Kalluri
Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria
J. Biol. Chem., April 4, 2003; 278(15): 12605 - 12608.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.